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ABSTRACT 
 
 
 
Unprotected linear peptides containing N-terminal cysteines and another cysteine residue can be simultaneously 
cyclized and derivatized using 2,2-disubstituted cyclopentenediones. High yields of cyclic peptide conjugates may 
be obtained in short reaction times using only a slight excess of the cyclopentenedione moiety under TEMPO 
catalysis and in the presence of LiCl. 
Cyclic peptides have found wide application in the 
biological and medicinal fields. These compounds have 
been investigated to inhibit amyloid fibrillation,1 as 
antibacterial2 and antifungal3 agents, in the treatment of 
tumours4 and to regulate protein-protein interactions 
through epitope mimicking,5 among others.  
Further functionalization of cyclic peptides can 
ameliorate their properties or those of the molecule to 
which they are attached. For example, conjugation to 
proteins6 may enhance protein transduction, and 
conjugation to fluorophores7 is important to obtain 
traceable systems. As for cyclic RGD peptides, which 
are widely utilized to selectively target some cancer 
cells, they need to be conjugated to drugs, other 
biomolecules or radiolabels to be used in cancer therapy 
and diagnosis.8 For these reasons, methodologies 
allowing for the simultaneous cyclization and 
derivatization of peptides are of great interest, and in the 
last decade different groups have conducted research in 
this area.9 
We have recently described that 2,2-disubstituted 
cyclopent-4-ene-1,3-diones (CPDs) selectively react 
with N-terminal cysteines in the presence of other 
cysteines.10 After formation of the Michael-type adduct 
(with a mass of M Da), intramolecular imine formation 
furnishes an intermediate (M-18 Da adduct), which is 
subsequently oxidized (likely by oxygen) to generate a 
conjugated structure with a mass of M-20 Da that 
exhibits a UV maximum at 330 nm (Scheme 1). 
 
 
Scheme 1. Outcome of the reaction between CPDs and N-
terminal 
cysteines.  
 
 
 
 
 
 
 
  
Since the M-20 conjugated adducts may undergo a 
second nucleophilic addition, we decided to explore the 
possibility of cyclizing peptides through reaction with 
another cysteine in the same peptide chain (Scheme 2a). 
This manuscript describes different steps of the 
optimization of the cyclization reaction, which may 
provide labeled cyclic peptides in cases where suitably 
derivatized CPDs are used. Parameters affecting the 
reaction outcome and kinetics have been optimized, and 
product stability has been examined. In all cases 
formation of a cyclic molecule was confirmed by mass 
spectrometry and UV spectroscopy, and NMR proof was 
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Scheme 2. a) Different steps in the intramolecular cyclization reaction (M is the mass of the Michael-type adduct that would be 
generated by a simple CPD-thiol addition, see Scheme 1). R may incorporate a labeling moiety, see Figure 1). b) Major side products 
formed (oligomers were not observed, probably because of the high dilution reaction conditions). c) Cyclic peptide 3a. 
 
 
 
 
 
 
 
obtained for one peptide. The M-20 cyclic precursor 
(Scheme 2a) was occasionally detected (HPLC-MS). 
Figure 1 assembles the structures of the CPDs and 
peptides utilized in the different cyclization reactions. In 
addition to model compounds such as peptides 1-4 and 
CPD a, CPDs carrying biotin and dansyl labeling 
moieties (b and c, respectively), the linear precursors of 
oxytocin11 (5) and a bombesin agonist12 (6), and epimeric 
peptides 7-9 (see below for an explanation) were used. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structures of the different peptides and CPDs used in 
this work. Lower case letters describe D-amino acids.  
In preliminary experiments, aqueous solutions of CPD 
a and peptides 1 or 2 were heated (60 oC), and formation 
of the two expected diastereomeric cyclic adducts 
(differing in the configuration of C2 in the CPD ring) 
was confirmed by the appearance of two peaks with a 
mass of M-22 Da (HPLC-MS analysis) and a UV 
maximum around 375 nm (see Scheme 2a). However, 
both crudes, and especially that of 1a, were rather 
complex, which evidenced that cyclization conditions 
had to be fine-tuned.  
In an attempt to accelerate the reaction, 1 and a were 
reacted under conditions enhancing the nucleophilicity 
of thiol groups, at pH=8 (phosphate buffer) and in the 
presence of 1-2 equiv of different bases (NaOH, Et3N). 
Yet, these experiments rendered complex crudes, with 
the undesired disulfide as the main product (Scheme 2b). 
Prompted by the fact that some thiol-involving 
conjugate additions are radical reactions,13 the addition 
of 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) and 
O2 (balloon) was assayed. TEMPO provided better 
results than O2, although formation of the cyclic 
disulfide and the product with the internal cysteine 
oxidized (see Scheme 2b) were observed as competing 
side-reactions. Therefore, the protocol for TEMPO 
addition (amount and timing) together with peptide 
concentration, CPD excess and reaction temperature 
were adjusted to reduce the amount of by-products.  
With the so far best-working conditions (protocol 1, 
Supporting Information (SI), section 4) cyclic peptides 
1a and 2a could be satisfactorily obtained employing 
only 0.4 equiv of TEMPO (80-85 % HPLC-based yield; 
see entries 1 and 2 of Table 1). In parallel with these 
experiments, the 3 + a reaction was carried out at a 
higher scale (SI, section 5). Both diastereomers of cyclic 
peptide 3a (Scheme 2c, M-22 Da products) were 
isolated by HPLC and fully characterized by NMR. 
HMBC experiments allowed to observe the correlation 
between the olefin carbons of the CPD ring and the β-
hydrogens of both the C- and N-terminal cysteines, 
confirming that cyclization had taken place. 
The conjugated system generated upon cyclization 
was found to contribute to the peptide absorbance at 280 
nm (UV-based yields exceeded 100%), which ruled out 
quantification of the cyclic conjugates from the 
absorbance of Tyr and/or Trp.14 To allow for amino acid-
independent cyclic peptide quantification, the molar 
absorption coefficient of the 4,5-disubstituted CPD ring 
around 375 nm was determined (12215 M-1 cm-1 at 373 
nm in water, and 12645 M-1 cm-1 at 365 nm in methanol) 
from the UV spectra of solutions of 3a (quantified by 
NMR using 1,4-dioxane as internal standard15). 
At that point, more challenging reactions such as 
those involving CPDs b and c and the linear precursor of 
oxytocin (5) were carried out (Table 1, entries 3-5). 
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Table 1. Reaction times and yields for the cyclizations carried 
out using the first set of fine-tuned conditionsa 
entry reactiona product time (h)b yield (%)c 
1 1 + a 1a 2.75 81 
2 2 + a 2a 2.25 84 
3 1 + b 1b 5.5 64 
4 1 + c 1c 6.5 49 
5 5 + a 5a 4d <30 
aCyclization reactions were carried out using protocol 1 (SI, section 4). 
bTime needed for the complete disappearance of the corresponding M-
20 Da adduct (the M-22 Da cyclic peptide is then completely formed). 
cHPLC-based cyclization yield at that time (280 nm). Products were 
not isolated. dA large amount of side-products was observed (SI, 
section 7).  
Use of CPD a to cyclize different peptides (1, 2 and 5, 
entries 1, 2 and 5 in Table 1) showed that the smallest 
cycle (19-membered ring, 2 + a reaction) was the one 
formed more rapidly. Yet, reaction 1 + a was faster than 
5 + a, which indicates that peptide sequence, in addition 
to ring size (both reactions afford 22-membered rings in 
this case), influences the kinetics of the cyclization. 
Peptides 3 and 4, which only differ in the amino acid 
sequence, were also reacted with CPD a (see SI, section 
8). 3 cyclized more rapidly than 4, which may suggest 
that aromatic amino acids adjacent to the N-terminal Cys 
have a negative impact on the cyclization rate.  
Reaction rates were also affected by the substituent at 
the 2 position of the CPD, as shown by the experiments 
in which peptide 1 was reacted with the three CPDs (a, b 
and c, cf. entries 1, 3 and 4 in Table 1). These results 
suggest that large substituents have a negative impact on 
cyclization, but this trend is not reproduced by results 
assembled in Table 2 (see below, entries 3-5 and 10-12).  
In all cases longer reaction times correlated with 
lower cyclization yields, as slower rates cause longer 
exposure of the internal thiol to the free radical TEMPO, 
which favors oxidation to sulfonic acid.  
To overcome this problem, the effect of a chaotropic 
agent such as LiCl in the reaction mixture was evaluated. 
Here, the troublesome 5 + a reaction was selected as 
model system. Different amounts of LiCl were added to 
the reaction mixture, and the conversion of the M-20 Da 
adduct to the cyclic product was studied (see SI, section 
9). The positive effect of LiCl was demonstrated, and a 
clear correlation between the amount of LiCl and the 
cyclization rate could be observed. Although the best 
results were obtained with the highest salt content, a 2 M 
LiCl concentration was deemed the best option to 
accelerate the reaction while reducing possible elution 
problems during HPLC purification. The cyclization 
protocol was therefore re-optimized in the presence of 
LiCl. This resulted in an improved procedure (protocol 
2, section 4 of the SI) in which peptide, CPD and 
TEMPO (1:1.5:0.2 molar ratio) are incubated at 60 ºC16 
in 2 M aq. LiCl for 1 h. 0.2 equiv of TEMPO are then 
added, and every 30 min until completion of the reaction 
(as assessed by HPLC). Cyclizations normally take place 
in less than 2 h. Solvent composition (water or 
water/methanol mixtures) has to be adjusted for each 
CPD on the basis of its solubility. 
Protocol 2 was then used to synthesize different cyclic 
peptides, generally with satisfactory results (Table 2; in 
the 10 + a reaction a longer reaction time was required 
to attain a satisfactory cyclization yield). Yet, a large 
amount of contaminants with the same mass and UV 
profile but different retention times was found to 
accompany purified compounds 1b, 1c, 5b and 5c (and 
other by-products, in the case of 5b). Revision of the 
isolation procedure revealed that these peptides had been 
lyophilized at the same time as NH3- or Et3N-containing 
solutions. We surmised that these impurities resulted 
from epimerization of the N-terminal cysteine, which is 
likely favored by the high resonance-stabilization of the 
intermediate anion (see SI, page S2). Studies carried out 
with peptide 1b showed that the cyclic peptides 
remained stable while in the reaction crude at room 
temperature, at acidic pH, and in water or aqueous 
organic solvents, but not in basic conditions or after 
prolonged heating. 
To confirm the cysteine epimerization hypothesis, the 
two diastereomers of cyclic peptides 1b and 7b (1 and 7 
differ in the configuration of the N-terminal Cys) were 
isolated. Next, each isomer of 1b was incubated at pH 
9.0 for 20 min, and the resulting crude analyzed by 
HPLC. A new compound with the same mass and UV 
properties had appeared in both cases. Coinjection 
experiments revealed that each of the newly formed 
products coeluted with one of the isomers of 7b, thus 
proving that epimerization had occurred (Figure 2). 
 
 
Figure 2. HPLC-MS traces (280 nm) showing that one of the 
isomers of 1b is partially transformed into one of the isomers 
of 7b after treatment with a base (AU = absorbance units).  
On the basis of these data, D-Cys was employed for 
the synthesis of different labeled cyclic peptides, which 
were formed in good yields (see Table 2, entries 8-14), 
and could be isolated as stereoisomerically pure 
compounds except in one case. 
Additional stability experiments were carried out with 
each of the two isomers of cyclic peptides 5a, 6a, 8a, 9a 
and 9b (incubation at pH 7.4 PBS buffer for 12 and 24 h, 
and at pH 9.0 for 20 min). HPLC monitoring revealed 
that the epimerization extent was largely compound- 
dependent, although in general L-Cys-containing  
 
Table 2. Reaction yields for the cyclization and derivatization reactions carried out using the finally optimised procedure, and stability 
of the isolated products to bases 
Peptides containing L-Cys at the N-terminal position Peptides containing D-Cys at the N-terminal position 
entry reactiona product yield (%)b 
non-epimerized 
product (%)c entry reactiona product yield (%)b 
non-epimerized 
product (%)c 
isomer 1 isomer 2 isomer 1 isomer 2 
1 1 + b 1b 76/34 64 83 8 7 + b 7b 76/40 95 93 
2 1 + c 1c 75/37 n.d. n.d. 9 7 + c 7c 66/40 n.d. n.d. 
3 5 + a 5a 80 87 6 10 8 + a 8a 72 94 99 
4 5 + b 5b 65 n.d. n.d. 11 8 + b 8b 77/33 n.d. n.d. 
5 5 + c 5c 84/33 n.d. n.d. 12 8 + c 8c 82/45 n.d. n.d. 
6 6 + a 6a 36d 45 59 13 9 + a 9a 63 54 40 
7 6 + b 6b 25d n.d.e n.d.e 14 9 + b 9bf 74/22 100 36 
      15 10 + a 10a 68/47g n.d. n.d. 
aCyclization reactions were carried out using protocol 2 (SI, section 4; 2 h reaction time). Water was used as solvent except in experiments corresponding 
to entries 2, 4, 5, 9 and 12, where a 1:1 MeOH/H2O mixture was employed. bHPLC-based cyclization yield after 2 h (280 nm)/Isolated yield (after HPLC 
purification, SI section 11). cStability determined at pH 7.4 after 12 h incubation (n.d. = not determined). dSeveral side reactions took place upon 
cyclization of peptide 6. eThese products could not be isolated due to the complexity of the crude. fIsomer 2 of product 9b was isolated as a mixture of 
epimers at the N-terminal Cys. gReaction time was 3.5 h in this case (total amount of TEMPO: 1.4 equiv).  
products tended to epimerize faster than those containing 
D-Cys. Table 2 shows that the amount of non-epimerized 
product is usually higher for the peptides with D-Cys 
than for those with L-Cys (cf. entries 1 and 8, 3 and 10, 
and 6 and 13; see SI, section 10). Even though it yields 
stereoisomeric compounds, we believe that this 
methodology may find application, since synthetic 
methods providing mixtures of isomers have found use 
in bioconjugation (inverse electron demand Diels-Alder 
cycloadditions, reactions between azides and strained 
cyclooctynes) and in therapy (three phosphorothioate 
oligonucleotides have been approved as drugs). 
In conclusion, this work has demonstrated that CPDs 
can be used to simultaneously cyclize and derivatize 
peptides with two cysteine residues, of which one at the 
N-terminus. This should not be a limitation, since several 
methods (including SPPS) allow this residue to be 
introduced into peptides and proteins.17 
Cyclizations have furnished 19-, 22-, 25 and 31-
membered rings, and take place in good yields and 
relatively short reaction times using TEMPO as catalyst 
and in the presence of LiCl. Different data (MS, UV, and 
also NMR) have confirmed that cyclization does take 
place.  
Structural parameters affecting the reaction rate and 
outcome as well as the stability of the conjugated cyclic 
peptides to bases have been examined. Our results point 
to peptide sequence as influencing the cyclization 
kinetics, and show that peptides with D-Cys at the N-
terminus furnish cycles generally more stable. For this 
reason, introduction of D-Cys at the N-terminal position 
is recommended. However, structural studies out of the 
scope of this work should be performed to establish the 
ultimate reasons behind the observation that both the 
CPD and peptide nature have a profound effect on the 
reaction rate, as well as the different chemical behavior 
of the L- and D-epimers. 
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